Q-omics provides the consensus-scored LINC01693 profile across patient tissues and cancer cell-line models. LINC01693 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LINC01693 is differentially expressed in 9, with the highest sampling consensus in KIRP. Additionally, LINC01693 RNA expression shows 8,981 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight BLCA, and KIRP as cancer lineages where LINC01693 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01693 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01693 survival associations across molecular data types. LINC01693 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01693 RNA expression–survival associations across cancer types. High LINC01693 expression shows unfavorable associations in LGG, LUSC, BRCA and SKCM, but favorable associations in BLCA and UCEC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for LINC01693 RNA expression.
This table summarizes LINC01693 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01693. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01693 shows lower tumor expression in KICH and higher tumor expression in KIRP, KIRC, LIHC, THCA and CHOL. The KIRP box plot shows higher LINC01693 RNA expression in tumor versus normal tissue (log2 FC = +0.796, t-test p < 0.001).
This table shows molecular features associated with LINC01693 in patient tissues and cancer cell lines. In patient samples, LINC01693 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
